BR112015022464A2 - anticorpos anti-cd52, seu método de preparação bem como seus usos, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, linhagem celular isolada, e composição - Google Patents

anticorpos anti-cd52, seu método de preparação bem como seus usos, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, linhagem celular isolada, e composição

Info

Publication number
BR112015022464A2
BR112015022464A2 BR112015022464A BR112015022464A BR112015022464A2 BR 112015022464 A2 BR112015022464 A2 BR 112015022464A2 BR 112015022464 A BR112015022464 A BR 112015022464A BR 112015022464 A BR112015022464 A BR 112015022464A BR 112015022464 A2 BR112015022464 A2 BR 112015022464A2
Authority
BR
Brazil
Prior art keywords
isolated
antibodies
vector
preparation
nucleic acid
Prior art date
Application number
BR112015022464A
Other languages
English (en)
Portuguese (pt)
Inventor
Qun Pan Clark
Qiu Huawei
Sendak Rebecca
Rong Wei Ronnie
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50391542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015022464(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BR112015022464A2 publication Critical patent/BR112015022464A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112015022464A 2013-03-15 2014-03-13 anticorpos anti-cd52, seu método de preparação bem como seus usos, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, linhagem celular isolada, e composição BR112015022464A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361794576P 2013-03-15 2013-03-15
PCT/US2014/026159 WO2014151644A2 (en) 2013-03-15 2014-03-13 Anti-cd52 antibodies

Publications (1)

Publication Number Publication Date
BR112015022464A2 true BR112015022464A2 (pt) 2017-10-24

Family

ID=50391542

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022464A BR112015022464A2 (pt) 2013-03-15 2014-03-13 anticorpos anti-cd52, seu método de preparação bem como seus usos, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, linhagem celular isolada, e composição

Country Status (35)

Country Link
US (2) US9708407B2 (https=)
EP (1) EP2970467B1 (https=)
JP (2) JP6482524B2 (https=)
KR (1) KR20150131286A (https=)
CN (1) CN105209495B (https=)
AR (1) AR095199A1 (https=)
AU (1) AU2014233685B2 (https=)
BR (1) BR112015022464A2 (https=)
CA (1) CA2906539A1 (https=)
CL (1) CL2015002705A1 (https=)
CR (1) CR20150547A (https=)
CY (1) CY1121795T1 (https=)
DK (1) DK2970467T3 (https=)
DO (1) DOP2015000211A (https=)
EA (1) EA031730B1 (https=)
ES (1) ES2710976T3 (https=)
GT (1) GT201500267A (https=)
HR (1) HRP20190085T1 (https=)
HU (1) HUE041796T2 (https=)
IL (1) IL241410A0 (https=)
LT (1) LT2970467T (https=)
MA (1) MA38485A1 (https=)
MX (1) MX2015012991A (https=)
NZ (1) NZ631473A (https=)
PE (1) PE20151757A1 (https=)
PH (1) PH12015501932A1 (https=)
PL (1) PL2970467T3 (https=)
PT (1) PT2970467T (https=)
SG (1) SG11201506932SA (https=)
SI (1) SI2970467T1 (https=)
TN (1) TN2015000415A1 (https=)
TR (1) TR201900638T4 (https=)
TW (1) TWI644923B (https=)
UY (1) UY35440A (https=)
WO (1) WO2014151644A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2998405B1 (en) 2009-05-13 2019-12-11 Genzyme Corporation Anti-human cd52 immunoglobulins
CA2761885A1 (en) 2009-05-13 2010-11-18 Genzyme Corporation Methods and compositions for treating lupus
CN110351062B (zh) * 2014-01-28 2022-03-01 华为技术有限公司 数据传输的指示方法、接入点和终端
US20200299399A1 (en) * 2017-04-21 2020-09-24 Genzyme Corporation Treatment of Multiple Sclerosis with Anti-CD52 Antibodies
EP3752193A4 (en) * 2018-02-13 2022-02-23 Merck Sharp & Dohme Corp. METHODS OF TREATMENT OF CANCER WITH ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES
PE20220568A1 (es) 2019-05-21 2022-04-20 Novartis Ag Moleculas de union a cd19 y usos de las mismas
WO2021022044A1 (en) * 2019-07-31 2021-02-04 Forty Seven, Inc. Depletion regimes for engineered t-cell or nk-cell therapy
EP4574840A1 (en) * 2022-08-15 2025-06-25 The University of Tokyo Method for producing immunoglobulin or multimer immunoglobulin using filamentous fungus
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1987006265A1 (fr) 1986-04-17 1987-10-22 Kyowa Hakko Kogyo Co., Ltd. Nouveaux composes dc-88a et dc-89a1, et procede pour leur preparation
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2598116B2 (ja) 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
JP2510335B2 (ja) 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
US5187186A (en) 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9108056D0 (en) 1991-04-16 1991-06-05 Hale Geoffrey Synthetic antigen
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5269388A (en) 1991-11-12 1993-12-14 Stress-Tek, Inc. Weighing bed
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
CA2165819C (en) 1994-04-22 2005-12-27 Nobuyoshi Amishiro Dc-89 derivatives
US5550246A (en) 1994-09-07 1996-08-27 The Scripps Research Institute Calicheamicin mimics
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
ES2276708T3 (es) 1999-11-24 2007-07-01 Immunogen, Inc. Agentes citotoxicos que comprenden taxanos y su uso terapeutico.
BRPI0108923B8 (pt) 2000-03-03 2021-05-25 Cambridge Antibody Tech Limited elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20020132983A1 (en) 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
JP4063769B2 (ja) 2001-12-28 2008-03-19 中外製薬株式会社 タンパク質安定化方法
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
WO2004042032A2 (en) 2002-11-01 2004-05-21 The Ohio State University Research Foundation Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
CN1225480C (zh) 2002-12-18 2005-11-02 马菁 抗cd52单克隆抗体、其编码序列及应用
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
AU2004226492A1 (en) 2003-03-31 2004-10-14 Kirin Beer Kabushiki Kaisha Method of inducing differentiation and proliferating regulatory T cell by anti-CD52 antibody and medicinal composition therefor
WO2005017149A1 (en) 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
WO2005042581A2 (en) 2003-11-01 2005-05-12 Biovation Ltd. Modified anti-cd52 antibody
US20060204496A1 (en) 2003-11-28 2006-09-14 Tetsuo Kojima Agonist antibody against heteroreceptor
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
JP2009504136A (ja) 2005-05-24 2009-02-05 アベスタゲン リミテッド 慢性リンパ性白血病治療のためのｃｄ５２に対するモノクローナル抗体産生のための組み換え法
DK1888113T3 (da) * 2005-05-27 2014-09-01 Biogen Idec Inc Tweak-bindende antistoffer
WO2007076927A1 (en) 2005-12-30 2007-07-12 Merck Patent Gmbh Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130
WO2007121233A1 (en) 2006-04-12 2007-10-25 Genzyme Corporation Methods of treating autoimmune diseases
US9498528B2 (en) 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
KR101583587B1 (ko) 2006-09-13 2016-01-08 젠자임 코포레이션 캠패스-1ｈ에 의한 다발성 경화증 (ｍｓ)의 치료
JP5337055B2 (ja) * 2007-02-28 2013-11-06 メルク・シャープ・アンド・ドーム・コーポレーション 免疫性障害の処置のための組合せ治療
US20100178293A1 (en) 2007-06-22 2010-07-15 Olaf Weber Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease
WO2010132697A2 (en) 2009-05-13 2010-11-18 Genzyme Corporation Methods and compositions for treatment
EP2998405B1 (en) * 2009-05-13 2019-12-11 Genzyme Corporation Anti-human cd52 immunoglobulins
CA2761885A1 (en) 2009-05-13 2010-11-18 Genzyme Corporation Methods and compositions for treating lupus
SI2454284T1 (en) * 2009-07-15 2018-07-31 Aimm Therapeutics B.V. Compounds that specifically bind to Gram-positive bacteria
DK2593594T3 (en) * 2010-07-16 2017-12-11 Adimab Llc ANTIBODY LIBRARIES

Also Published As

Publication number Publication date
EP2970467B1 (en) 2018-10-17
EA031730B1 (ru) 2019-02-28
JP2016518333A (ja) 2016-06-23
PE20151757A1 (es) 2015-12-03
CY1121795T1 (el) 2020-07-31
DK2970467T3 (en) 2019-02-11
HK1219963A1 (en) 2017-04-21
SI2970467T1 (sl) 2019-03-29
HUE041796T2 (hu) 2019-05-28
HRP20190085T1 (hr) 2019-03-08
US20170349665A1 (en) 2017-12-07
JP2019069960A (ja) 2019-05-09
TN2015000415A1 (en) 2017-01-03
MA38485A1 (fr) 2017-06-30
WO2014151644A3 (en) 2015-01-15
PT2970467T (pt) 2019-01-28
TR201900638T4 (tr) 2019-03-21
PL2970467T4 (pl) 2019-07-31
WO2014151644A2 (en) 2014-09-25
TWI644923B (zh) 2018-12-21
EP2970467A2 (en) 2016-01-20
GT201500267A (es) 2017-12-15
AR095199A1 (es) 2015-09-30
KR20150131286A (ko) 2015-11-24
CA2906539A1 (en) 2014-09-25
ES2710976T3 (es) 2019-04-29
IL241410A0 (en) 2015-11-30
DOP2015000211A (es) 2015-11-30
NZ631473A (en) 2017-09-29
CN105209495A (zh) 2015-12-30
US9708407B2 (en) 2017-07-18
MX2015012991A (es) 2015-12-15
US20160024219A1 (en) 2016-01-28
PL2970467T3 (pl) 2019-07-31
TW201522373A (zh) 2015-06-16
CR20150547A (es) 2016-01-08
AU2014233685B2 (en) 2019-02-28
LT2970467T (lt) 2019-02-11
CN105209495B (zh) 2020-06-26
PH12015501932A1 (en) 2016-01-04
UY35440A (es) 2014-10-31
SG11201506932SA (en) 2015-09-29
JP6482524B2 (ja) 2019-03-13
AU2014233685A1 (en) 2015-10-01
EA201591796A1 (ru) 2016-01-29
CL2015002705A1 (es) 2016-04-22

Similar Documents

Publication Publication Date Title
BR112015022464A2 (pt) anticorpos anti-cd52, seu método de preparação bem como seus usos, molécula de ácido nucleico isolada, vetor, célula hospedeira isolada, linhagem celular isolada, e composição
BR112015022208A2 (pt) proteínas de fusão que compreendem pdgf e partes de ligação de vegf, seu método de produção bem como seus usos, composição, ácido nucleico, célula hospedeira, vetor, partícula de raav e seu método de produção
MY193112A (en) Anti pd-1 and anti-lag3 antibodies for cancer treatment
MX2014011066A (es) Moleculas de union novedosas con actividad antitumoral.
BR122020002402B8 (pt) Proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, célula hospedeira recombinante, métodos de confecção da referida proteína de ligação e uso da mesma
HRP20251020T1 (hr) Proteini s jednolančanim varijabilnim fragmentom koji vežu cd3
BR112012004823A8 (pt) Anticorpo ou fragmento de ligação de antígeno do mesmo, uso de um anticorpo ou um fragmento de ligação de antígeno do mesmo, e composição farmacêutica
BR112015017338A8 (pt) anticorpo ou proteína isolada, sua composição farmacêutica, seu uso, seu processo de produção, molécula de ácido nucleico isolada, vetor de clonagem ou de expressão e célula hospedeira
SA522432139B1 (ar) بروتينات ربط متعددة الخصوصية لمعالجة السرطان
BR112020013236A2 (pt) proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
AR080446A1 (es) Polipeptidos de union a a-beta (beta amiloide)
AR090047A1 (es) Dominio variable dual de inmunoglobulinas y sus usos
BRPI0915928B8 (pt) anticorpo isolado ou proteína funcional e composição farmacêutica compreendendo os mesmos
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
EA201892774A1 (ru) Антитела
BR112012025730A8 (pt) anticorpos anti-erbb3, seus usos e seu processo de produção, ácidos nucleicos, vetores de expressão, células hospedeiras, bem como processo de produção de um polipeptídeo
PE20170704A1 (es) Agente terapeutico que induce citotoxicidad
BR112014032999A2 (pt) optimização de anticorpos que ligam o gene de ativação de linfócito 3 (lag-3), e uso dos mesmos
BR112014028785A2 (pt) proteínas de ligação a antígeno de st2
WO2014106015A3 (en) Multivalent binding protein compositions
EA201491494A1 (ru) Нацеливание на гликаны хондроитинсульфаты
BR112014023415A2 (pt) moléculas que se ligam a ang2
TW201129379A (en) Anti-Orai1 antigen binding proteins and uses thereof
EA201690503A1 (ru) Антитела
WO2016063026A3 (en) Selective nav protein binders

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements